$SURG
SurgePays, Inc. Stock $surg

$surg Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224044766 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue		$4.770M	$32.32M
YoY Change		-86.04%	-10.79%
Cost Of Revenue		$12.60M	$24.88M
YoY Change		-46.78%	-15.68%
Gross Profit		-$7.832M	$7.442M
YoY Change		-174.73%	10.67%
Gross Profit Margin		-164.21%	23.03%
Selling, General & Admin		$6.448M	$6.309M
YoY Change		90.27%	116.59%
% of Gross Profit			84.78%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$282.1K	$266.0K
YoY Change		33.59%	-1.05%
% of Gross Profit			3.57%
Operating Expenses		$6.448M	$6.575M
YoY Change		90.27%	106.77%
Operating Profit		-$14.28M	$866.3K
YoY Change		-301.38%	-75.56%
Interest Expense		$195.7K	-$102.5K
YoY Change		-349.39%	-80.3%
% of Operating Profit			-11.83%
Other Income/Expense, Net		$1.018K
YoY Change		-101.3%
Pretax Income		-$14.28M	$763.8K
YoY Change		-303.61%	-77.13%
Income Tax			-$2.265M
% Of Pretax Income			-296.56%
Net Earnings		-$14.28M	$3.021M
YoY Change		-301.51%	-0.77%
Net Earnings / Revenue		-299.29%	9.35%
Basic Earnings Per Share		-$0.73
Diluted Earnings Per Share		-$0.73	$0.20
COMMON SHARES
Basic Shares Outstanding	20.16M shares	19.74M shares	14.23M shares
Diluted Shares Outstanding		19.69M shares

Balance Sheet

Concept	2024 Q4	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$23.72M	$14.62M
YoY Change		86.31%	107.83%
Cash & Equivalents		$13.65M	$14.62M
Short-Term Investments		$10.07M
Other Short-Term Assets		$312.7K	$161.9K
YoY Change		58.01%	45.2%
Inventory		$8.363M	$9.047M
Prepaid Expenses		$312.7K	$161.9K
Receivables		$1.514M	$9.536M
Other Receivables		$0.00	$0.00
Total Short-Term Assets		$33.91M	$33.37M
YoY Change		-8.97%	21.05%
LONG-TERM ASSETS
Property, Plant & Equipment		$158.1K	$1.289M
YoY Change		-63.42%	100.37%
Goodwill		$4.167M	$1.667M
YoY Change		149.99%	0.0%
Intangibles		$1.636M	$2.126M
YoY Change		-28.54%	-23.51%
Long-Term Investments		$498.3K	$464.4K
YoY Change		10.77%	31.11%
Other Assets			$2.835M
YoY Change
Total Long-Term Assets		$7.590M	$8.559M
YoY Change		26.79%	32.9%
TOTAL ASSETS
Total Short-Term Assets		$33.91M	$33.37M
Total Long-Term Assets		$7.590M	$8.559M
Total Assets		$41.50M	$41.93M
YoY Change		-4.02%	23.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$3.636M	$7.487M
YoY Change		-53.59%	-0.34%
Accrued Expenses		$50.42K	$43.14K
YoY Change		19.45%	9.24%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$4.585M
YoY Change		-100.0%	72.99%
Long-Term Debt Due		$1.647M
YoY Change
Total Short-Term Liabilities		$5.434M	$12.71M
YoY Change		-62.48%	-45.85%
LONG-TERM LIABILITIES
Long-Term Debt		$2.776M	$460.5K
YoY Change		-38.9%	-90.83%
Other Long-Term Liabilities		$13.13K	$356.3K
YoY Change		-96.43%	-10.8%
Total Long-Term Liabilities		$2.789M	$816.8K
YoY Change		-43.2%	-84.93%
TOTAL LIABILITIES
Total Short-Term Liabilities		$5.434M	$12.71M
Total Long-Term Liabilities		$2.789M	$816.8K
Total Liabilities		$8.224M	$13.68M
YoY Change		-57.6%	-52.65%
SHAREHOLDERS EQUITY
Retained Earnings		-$41.10M	-$15.19M
YoY Change		125.75%	-57.59%
Common Stock		$19.94K	$14.40K
YoY Change		38.98%	2.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$146.8K	$485.1K
YoY Change
Treasury Stock Shares
Shareholders Equity		$33.16M	$28.25M
YoY Change
Total Liabilities & Shareholders Equity		$41.50M	$41.93M
YoY Change		-4.02%	23.3%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	-$14.28M	$3.021M
YoY Change	-301.51%	-0.77%
Depreciation, Depletion And Amortization	$282.1K	$266.0K
YoY Change	33.59%	-1.05%
Cash From Operating Activities	-$13.32M	$1.958M
YoY Change	-264.28%	-58.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$10.59M	$0.00
YoY Change	814261.54%	-100.0%
Cash From Investing Activities	-$10.59M	$0.00
YoY Change	814261.54%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-873.7K	-67.04K
YoY Change	55.3%	-98.71%
NET CHANGE
Cash From Operating Activities	-13.32M	1.958M
Cash From Investing Activities	-10.59M	0.000
Cash From Financing Activities	-873.7K	-67.04K
Net Change In Cash	-24.78M	1.891M
YoY Change	-428.43%	-320.76%
FREE CASH FLOW
Cash From Operating Activities	-$13.32M	$1.958M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001392694
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2023Q4	SURG	Construction In Progress ConstructionInProgress		usd
CY2024Q3	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent		usd
CY2024Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2023Q3	SURG	Loss On Lease Termination Net LossOnLeaseTerminationNet		usd
	SURG	Loss On Lease Termination Net LossOnLeaseTerminationNet		usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2023Q3	SURG	Unrealized Gain Losses On Investments UnrealizedGainLossesOnInvestments		usd
	SURG	Unrealized Gain Losses On Investments UnrealizedGainLossesOnInvestments		usd
CY2023Q3	SURG	Dividends Interest And Other Income Investments DividendsInterestAndOtherIncomeInvestments		usd
	SURG	Dividends Interest And Other Income Investments DividendsInterestAndOtherIncomeInvestments		usd
CY2024Q3	SURG	Gain Loss On Investments In Center Com GainLossOnInvestmentsInCenterCom		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	SURG	Stock Issued During Period Value Exercise Of Warrants Cashless StockIssuedDuringPeriodValueExerciseOfWarrantsCashless		usd
	SURG	Recognition Of Stock Based Compensation Unvested Shares Related Party RecognitionOfStockBasedCompensationUnvestedSharesRelatedParty		usd
	SURG	Interest Expene Adjustment Sba Loans InterestExpeneAdjustmentSbaLoans		usd
	SURG	Rightofuse Asset Lease Payment Adjustment True Up RightofuseAssetLeasePaymentAdjustmentTrueUp		usd
	SURG	Cash Paid For Lease Termination CashPaidForLeaseTermination		usd
	SURG	Loss On Lease Termination Net LossOnLeaseTerminationNet		usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes		usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable		usd
	SURG	Increase Decrease In Installment Sale Liability Net IncreaseDecreaseInInstallmentSaleLiabilityNet		usd
	us-gaap	Repayments Of Advances For Construction RepaymentsOfAdvancesForConstruction		usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware		usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	SURG	Cash Paid As Direct Offering Costs CashPaidAsDirectOfferingCosts		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	SURG	Treasury Shares Repurchased Share Buybacks TreasurySharesRepurchasedShareBuybacks		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	SURG	Reclassification Of Sba Note Payable Government To Note Payable ReclassificationOfSbaNotePayableGovernmentToNotePayable		usd
	SURG	Exercise Of Warrants Cashless ExerciseOfWarrantsCashless		usd
	SURG	Rightofuse Asset Obtained In Exchange For New Operating Lease Liability RightofuseAssetObtainedInExchangeForNewOperatingLeaseLiability		usd
	SURG	Goodwill Non Cash GoodwillNonCash		usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2024Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Capitalized Computer Software Period Increase Decrease CapitalizedComputerSoftwarePeriodIncreaseDecrease		usd
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares		shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares		shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableNumber		shares
CY2024Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageExercisePrice
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2023Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsUnvested
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted
CY2024Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue		usd
CY2024Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable		usd
CY2024Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2024Q3	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsUnvested
CY2024Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2023Q4	SURG	Installment Sale Liability InstallmentSaleLiability		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations		usd
	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations		usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost		usd
CY2023Q4	SURG	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization		usd
CY2024Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40992
	dei	Entity Registrant Name EntityRegistrantName	SURGEPAYS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0550352
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3124 Brother Blvd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 104
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bartlett
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	38133
	dei	City Area Code CityAreaCode	901
	dei	Local Phone Number LocalPhoneNumber	302-9587
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20161547	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13651559	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14622060	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	10068506	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1513996	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9536074	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	8363138	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9046594	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	312679	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	161933	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	33909878	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	33366661	usd
CY2024Q3	SURG	Construction In Progress ConstructionInProgress	518189	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	158092	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	361841	usd
CY2024Q3	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1636339	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2126470	usd
CY2024Q3	SURG	Internal Use Software Development Costs Net InternalUseSoftwareDevelopmentCostsNet	372303	usd
CY2023Q4	SURG	Internal Use Software Development Costs Net InternalUseSoftwareDevelopmentCostsNet	539424	usd
CY2024Q3	us-gaap	Goodwill Goodwill	4166782	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2024Q3	us-gaap	Investments Investments	498273	usd
CY2023Q4	us-gaap	Investments Investments	464409	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62786	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	387869	usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent	2835000	usd
CY2024Q3	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	6913334	usd
CY2023Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	8196805	usd
CY2024Q3	us-gaap	Assets Assets	41499493	usd
CY2023Q4	us-gaap	Assets Assets	41925307	usd
CY2024Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	100000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	570000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	20000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	50415	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	43137	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5434250	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12705044	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13132	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	356276	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2789256	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	816799	usd
CY2024Q3	us-gaap	Liabilities Liabilities	8223506	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13521843	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19931549	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19650779	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14403261	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14403261	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	19935	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	14404	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	74725651	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43421019	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	280770	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	485131	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41102720	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15186203	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	33157735	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	28249220	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	118252	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	154244	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33275987	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28403464	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41499493	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41925307	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4769697	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34160834	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51284531	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104823710	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	12602057	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	23680247	usd
	us-gaap	Cost Of Revenue CostOfRevenue	54377300	usd
	us-gaap	Cost Of Revenue CostOfRevenue	76622912	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6448402	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3389015	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20312185	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10201663	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	19050459	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	27069262	usd
	us-gaap	Costs And Expenses CostsAndExpenses	74689485	usd
	us-gaap	Costs And Expenses CostsAndExpenses	86824575	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14280762	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7091572	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23404954	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	17999135	usd
CY2024Q3	us-gaap	Interest Expense Other InterestExpenseOther	112814	usd
CY2023Q3	us-gaap	Interest Expense Other InterestExpenseOther	130335	usd
	us-gaap	Interest Expense Other InterestExpenseOther	362119	usd
	us-gaap	Interest Expense Other InterestExpenseOther	478928	usd
CY2024Q3	SURG	Loss On Lease Termination Net LossOnLeaseTerminationNet	194862	usd
	SURG	Loss On Lease Termination Net LossOnLeaseTerminationNet	194862	usd
CY2024Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	239	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	637107	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	183537	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	183537	usd
CY2024Q3	SURG	Unrealized Gain Losses On Investments UnrealizedGainLossesOnInvestments	38292	usd
	SURG	Unrealized Gain Losses On Investments UnrealizedGainLossesOnInvestments	38292	usd
CY2024Q3	SURG	Dividends Interest And Other Income Investments DividendsInterestAndOtherIncomeInvestments	86626	usd
	SURG	Dividends Interest And Other Income Investments DividendsInterestAndOtherIncomeInvestments	86626	usd
CY2023Q3	SURG	Gain Loss On Investments In Center Com GainLossOnInvestmentsInCenterCom	51894	usd
	SURG	Gain Loss On Investments In Center Com GainLossOnInvestmentsInCenterCom	33864	usd
	SURG	Gain Loss On Investments In Center Com GainLossOnInvestmentsInCenterCom	95636	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1018	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-78441	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	422445	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-383292	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14279744	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7013131	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22982509	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	17615843	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2970000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-14279744	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	7013131	usd
	us-gaap	Profit Loss ProfitLoss	-25952509	usd
	us-gaap	Profit Loss ProfitLoss	17615843	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4397	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-71170	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-35992	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	19209	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14275347	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	7084301	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25916517	usd
	us-gaap	Net Income Loss NetIncomeLoss	17596634	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.24
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.19
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19689010	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14291263	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18940689	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14205127	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19689010	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14507984	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18940689	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14740201	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28403464	usd
CY2024Q1	SURG	Stock Issued During Period Value New Issues Stock Issued For Cash StockIssuedDuringPeriodValueNewIssuesStockIssuedForCash	17249994	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-1395000	usd
CY2024Q1	SURG	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	8799257	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	411740	usd
CY2024Q1	SURG	Adjustments To Additional Paid In Capital Share Based Compensation Unvested Shares Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationUnvestedSharesRequisiteServicePeriodRecognition	1497417	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6196	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12164	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	1224595	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	56185499	usd
CY2024Q2	SURG	Adjustments To Additional Paid In Capital Share Based Compensation Unvested Shares Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationUnvestedSharesRequisiteServicePeriodRecognition	2981577	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-19431	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-12865765	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	46281880	usd
CY2024Q3	SURG	Adjustments To Additional Paid In Capital Share Based Compensation Unvested Shares Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationUnvestedSharesRequisiteServicePeriodRecognition	1758982	usd
CY2024Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	485131	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4397	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14275347	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33275987	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118253	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	307458	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9294	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-576	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4546341	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9980770	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	311186	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9294	usd
CY2023Q2	SURG	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	207240	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	90955	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	5965992	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16565437	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16565437	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	255640	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9294	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-71170	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	7084301	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	7084301	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	23843502	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	23843502	usd
	us-gaap	Profit Loss ProfitLoss	-25952509	usd
	us-gaap	Profit Loss ProfitLoss	17615843	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	693880	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	701279	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	70857	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	32426	usd
	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts	167121	usd
	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts	96795	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	411740	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	874284	usd
	SURG	Recognition Of Stock Based Compensation Unvested Shares Related Party RecognitionOfStockBasedCompensationUnvestedSharesRelatedParty	6237976	usd
	SURG	Interest Expene Adjustment Sba Loans InterestExpeneAdjustmentSbaLoans	19750	usd
	SURG	Rightofuse Asset Lease Payment Adjustment True Up RightofuseAssetLeasePaymentAdjustmentTrueUp	148584	usd
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	33864	usd
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	95637	usd
	SURG	Cash Paid For Lease Termination CashPaidForLeaseTermination	212175	usd
	SURG	Loss On Lease Termination Net LossOnLeaseTerminationNet	194862	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8022078	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	544063	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-683456	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3363165	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	150746	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	86355	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-2835000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-470000	usd
	SURG	Increase Decrease In Installment Sale Liability Net IncreaseDecreaseInInstallmentSaleLiabilityNet	-7097838	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-20000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-125110	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	84257	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-29230	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13412714	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8329698	usd
	us-gaap	Repayments Of Advances For Construction RepaymentsOfAdvancesForConstruction	518189	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	281304	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10068506	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10586695	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-281304	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17249994	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	8799257	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	207240	usd
	SURG	Cash Paid As Direct Offering Costs CashPaidAsDirectOfferingCosts	1395000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1132074	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1017385	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1531478	usd
	SURG	Repayments Of Short Term Debt Including Notes Payable RepaymentsOfShortTermDebtIncludingNotesPayable	8138	usd
	SURG	Repayments Of Short Term Debt Including Notes Payable RepaymentsOfShortTermDebtIncludingNotesPayable	10976	usd
	SURG	Treasury Shares Repurchased Share Buybacks TreasurySharesRepurchasedShareBuybacks	-485131	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23028908	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2352599	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-970501	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5695795	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14622060	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7035654	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13651559	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12731449	usd
	us-gaap	Interest Paid Net InterestPaidNet	372579	usd
	us-gaap	Interest Paid Net InterestPaidNet	209840	usd
	SURG	Reclassification Of Sba Note Payable Government To Note Payable ReclassificationOfSbaNotePayableGovernmentToNotePayable	498991	usd
	SURG	Exercise Of Warrants Cashless ExerciseOfWarrantsCashless	41	usd
	SURG	Termination Of Rou Operating Lease Assets And Liabilities TerminationOfRouOperatingLeaseAssetsAndLiabilities	309826	usd
	SURG	Rightofuse Asset Obtained In Exchange For New Operating Lease Liability RightofuseAssetObtainedInExchangeForNewOperatingLeaseLiability	98638	usd
	SURG	Goodwill Non Cash GoodwillNonCash	2500000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25916517	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13412714	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41102720	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33275987	usd
CY2024Q3	SURG	Working Capital WorkingCapital	28475628	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13651559	usd
CY2024Q3	us-gaap	Goodwill Goodwill	4166782	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2024Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_z6QdFR7z1Xp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zt0NnxabEzzk">Business Segments and Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. The Company manages its business as multiple reportable segments. See Note 10 regarding segment disclosure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SURGEPAYS, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEPTEMBER 30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Mobile Virtual Network Operator (SurgePhone and Torch Wireless) business segment made up approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ConsolidatedEntitiesAxis__custom--SurgePhoneAndTorchWirelessMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember_zXbRftd6Qkdc" title="Concentration risk percentage">81</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ConsolidatedEntitiesAxis__custom--SurgePhoneAndTorchWirelessMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember_ztMcb41Fu5Qd" title="Concentration risk percentage">85</span>% of total consolidated revenues for the nine months ended September 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues related to this business segment are <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ConsolidatedEntitiesAxis__custom--FederalCommunicationsCommissionMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zmBFoMHuYQo5" title="Concentrations risk percentage">100</span>% derived from programs administered by the Federal Communications Commission (FCC), and all funds related to these programs are received directly from organizations under the direction of the FCC and subject to administrative rulings, statutory changes, and other funding restrictions that could impact the Company’s operations in this segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable related to these programs made up <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ConsolidatedEntitiesAxis__custom--FederalCommunicationsCommissionMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z6ejsBIqByS4" title="Concentrations risk percentage">88</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ConsolidatedEntitiesAxis__custom--FederalCommunicationsCommissionMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zP0CShzWYkml" title="Concentrations risk percentage">98</span>% of accounts receivable at September 30, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customers in the United States accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_z239USpVibw9" title="Concentrations risk percentage">100</span>% of our revenues. We do not have any property or equipment outside of the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_z0eWDg4lsYFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zaIHc6IbC6w8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates during the nine months ended September 30, 2024 and 2023, respectively, include, allowance for doubtful accounts and other receivables, inventory reserves and classifications, valuation of loss contingencies, valuation of stock-based compensation, estimated useful lives related to intangible assets, capitalized internal-use software development costs, and property and equipment, implicit interest rate in right-of-use operating leases, uncertain tax positions, income tax payable and the valuation allowance on deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9950941	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	38291	usd
	us-gaap	Interest And Dividend Income Securities Other InterestAndDividendIncomeSecuritiesOther	85717	usd
	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	-6443	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10068506	usd
CY2024Q3	SURG	Impairment Losses On Marketable Securities ImpairmentLossesOnMarketableSecurities	0	usd
	SURG	Impairment Losses On Marketable Securities ImpairmentLossesOnMarketableSecurities	0	usd
CY2023Q3	SURG	Impairment Losses On Marketable Securities ImpairmentLossesOnMarketableSecurities	0	usd
	SURG	Impairment Losses On Marketable Securities ImpairmentLossesOnMarketableSecurities	0	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	10215	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	17525	usd
CY2024Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	8363138	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9046594	usd
CY2024Q3	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	0	usd
	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	0	usd
CY2023Q3	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	0	usd
	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	0	usd
	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	518189	usd
CY2024Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2024Q3	SURG	Software Development Costs Impairment Charges SoftwareDevelopmentCostsImpairmentCharges	0	usd
	SURG	Software Development Costs Impairment Charges SoftwareDevelopmentCostsImpairmentCharges	0	usd
CY2023Q3	SURG	Software Development Costs Impairment Charges SoftwareDevelopmentCostsImpairmentCharges	0	usd
	SURG	Software Development Costs Impairment Charges SoftwareDevelopmentCostsImpairmentCharges	0	usd
CY2024Q3	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	20000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51284531	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104823710	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2547000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2970000	usd
CY2024Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	100000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	570000	usd
CY2022Q4	us-gaap	Investments Investments	354206	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	110203	usd
CY2023Q4	us-gaap	Investments Investments	464409	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	33864	usd
CY2024Q3	us-gaap	Investments Investments	498273	usd
CY2024Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	51894	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	33864	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	95636	usd
CY2024Q3	us-gaap	Advertising Expense AdvertisingExpense	14351	usd
CY2023Q3	us-gaap	Advertising Expense AdvertisingExpense	89069	usd
	us-gaap	Advertising Expense AdvertisingExpense	42202	usd
	us-gaap	Advertising Expense AdvertisingExpense	137933	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3692429	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5628794	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14275346	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7084301	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25916517	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	17596634	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14275346	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7084301	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25916517	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	17596634	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19689010	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14291263	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18940689	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14205127	shares
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	216721	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	535074	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19689010	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14507984	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18940689	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14740201	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.24
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.19
CY2024Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	280770	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	280770	shares
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	485131	usd
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	485131	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	124767	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	124767	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zFAdLaug161g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zYWYcwsSYPok">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no material effect on the consolidated results of operations, stockholders’ equity, or cash flows.</span></p>
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1089038	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1089038	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	930946	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	727197	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	158092	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	361841	usd
CY2024Q3	us-gaap	Depreciation Depreciation	282067	usd
CY2023Q3	us-gaap	Depreciation Depreciation	211149	usd
	us-gaap	Depreciation Depreciation	861001	usd
	us-gaap	Depreciation Depreciation	701279	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4117181	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3627050	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1636339	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2126470	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	163377	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	163377	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	490131	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	490131	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	163377	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	653507	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	653507	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	165948	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1636339	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	387180	usd
CY2023	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	281304	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	668484	usd
CY2024Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	668484	usd
CY2024Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	55707	usd
CY2023Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	32265	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	167121	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	96795	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	474846	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	14323	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	460523	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	19750	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8138	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	472135	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	398485	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1700410	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1877749	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	11902	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	12308	usd
CY2024Q3	SURG	Long Term Debt Maturities Repayments Of Principal After Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour	422761	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	4423615	usd
CY2024Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	10068506	usd
	SURG	Cash Paid For Lease Termination CashPaidForLeaseTermination	212175	usd
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	309826	usd
	SURG	Finance Lease Right Of Use Liability FinanceLeaseRightOfUseLiability	-327139	usd
CY2024Q3	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	194862	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	194862	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	309826	usd
	SURG	Cash Paid For Lease Termination CashPaidForLeaseTermination	212175	usd
	SURG	Finance Lease Right Of Use Liability FinanceLeaseRightOfUseLiability	-327139	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	194862	usd
CY2024Q3	SURG	Operating Lease Right Of Use Non Asset OperatingLeaseRightOfUseNonAsset	62786	usd
CY2023Q4	SURG	Operating Lease Right Of Use Non Asset OperatingLeaseRightOfUseNonAsset	387869	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	63547	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	399413	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	70857	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	32426	usd
	SURG	Lease Liability Expense In Connection With Obligation Repayment LeaseLiabilityExpenseInConnectionWithObligationRepayment	-15748	usd
	SURG	Lease Liability Expense In Connection With Obligation Repayment LeaseLiabilityExpenseInConnectionWithObligationRepayment	-15789	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	86605	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	48215	usd
	SURG	Operating Cash Outflows From Operating Lease Obligation Payment OperatingCashOutflowsFromOperatingLeaseObligationPayment	84257	usd
	SURG	Operating Cash Outflows From Operating Lease Obligation Payment OperatingCashOutflowsFromOperatingLeaseObligationPayment	29230	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	98638	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	12681	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	52754	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	65435	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1888	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	63547	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	50415	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13132	usd
CY2021Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	73000	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Voting at 1 vote per share
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1395000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	15854994	usd
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	47386	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	411740	usd
CY2024Q3	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	5000000	usd
CY2024Q3	srt	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	20000	shares
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	280770	shares
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	485131	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Treasury Stock WeightedAverageNumberOfSharesTreasuryStock	1.73	shares
CY2024Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	81850	shares
CY2024Q4	us-gaap	Treasury Stock Value TreasuryStockValue	146836	usd
CY2024Q4	us-gaap	Weighted Average Number Of Shares Treasury Stock WeightedAverageNumberOfSharesTreasuryStock	1.79	shares
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	242615	shares
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1290024	usd
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriodGross	695000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.24
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	695000	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.24
	SURG	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriodGross	600000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.60
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	500000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.55
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	795000	shares
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.08
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1337990	usd
	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAveragePeriod	P0Y11M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6801	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y1M28D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableNumber	10203	shares
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageExercisePrice	16.00
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested And Non Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageRemainingContractualTerm	P4Y1M28D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	104272	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.45
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	5.53
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	121276	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.79
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	116174	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.43
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y7M9D
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableNumber	5101	shares
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Non Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageExercisePrice	16.00
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested And Non Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndNonExercisableWeightedAverageRemainingContractualTerm	P3Y1M28D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	121276	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.79
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M19D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	121276	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.79
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y8M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.06	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0388	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5681392	shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	5.05
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P1Y10M6D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue	10026387	usd
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5681392	shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	5.05
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P1Y10M6D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable	10026387	usd
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsUnvested	P0Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	43814	shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercised	4.73
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	63325	shares
CY2023	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	26.39
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5574253	shares
CY2023Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	4.81
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P0Y10M9D
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue	9348348	usd
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5574253	shares
CY2023Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	4.81
CY2023	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P0Y10M9D
CY2023Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable	9348348	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1953308	shares
	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercised	4.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	49792	shares
	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	8.15
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3571153	shares
CY2024Q3	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	4.81
	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P0Y1M9D
CY2024Q3	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	3571153	shares
CY2024Q3	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	4.81
	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P0Y1M9D
	us-gaap	Revenues Revenues	51284531	usd
	us-gaap	Revenues Revenues	104823710	usd
	us-gaap	Cost Of Revenue CostOfRevenue	54377300	usd
	us-gaap	Cost Of Revenue CostOfRevenue	76622912	usd
	us-gaap	Operating Expenses OperatingExpenses	20312185	usd
	us-gaap	Operating Expenses OperatingExpenses	10201663	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23404954	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	17999135	usd
CY2024Q3	us-gaap	Assets Assets	41499493	usd
CY2023Q4	us-gaap	Assets Assets	41925307	usd
CY2024Q3	us-gaap	Liabilities Liabilities	8223506	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13521843	usd
CY2024Q3	us-gaap	Assets Net AssetsNet	0	usd
CY2022	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	25000000	usd
CY2022Q4	SURG	Sales Of Asset Percentage SalesOfAssetPercentage	0.0985	pure
	SURG	Installment Sale Credit Description InstallmentSaleCreditDescription	3 month rolling average of 70% of the installment sale credit amount.
	SURG	Prepayment Penalty Description PrepaymentPenaltyDescription	The Company was subject to a cancellation fee of 3% during the first year and 2% during the second year.
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	2000	usd
	SURG	Default Rate Description DefaultRateDescription	For any unpaid amounts under this agreement, the Company was subject to a fee of 1.35% per month (16.2% annualized).
	us-gaap	Line Of Credit Facility Commitment Fee Percentage LineOfCreditFacilityCommitmentFeePercentage	0.02	pure
	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	5000000	usd
	us-gaap	Line Of Credit Facility Commitment Fee Description LineOfCreditFacilityCommitmentFeeDescription	For example, if the initial installment sale credit amount is $15,000,000, the credit availability fee would be $300,000 (2%). Any subsequent increase of $5,000,000 or more would result in an additional fee of $100,000 (2%). Commitment fees are paid over a period of 12 months as part of the Seller’s monthly invoicing.
CY2023	us-gaap	Professional Fees ProfessionalFees	491536	usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	135000	usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2835000	usd
	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	2970000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1964	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1964	pure
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5096000	usd
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	893000	usd
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.065	pure
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.065	pure
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1552000	usd
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	296000	usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1388000	usd
	SURG	Income Tax Expense Benefit Subtotal IncomeTaxExpenseBenefitSubtotal	-5260000	usd
	SURG	Income Tax Expense Benefit Subtotal IncomeTaxExpenseBenefitSubtotal	1189000	usd
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8230000	usd
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1189000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2970000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1292	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	3000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	5000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	178000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8077000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3844000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8258000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3849000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8037000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	790000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	221000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3059000	usd
CY2024Q3	SURG	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	52000	usd
CY2023Q4	SURG	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	224000	usd
CY2024Q3	SURG	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	165000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	217000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	224000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2835000	usd
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7247000	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd

Files In Submission

Name	View Source	Status
0001493152-24-044766-index-headers.html	Edgar Link	pending
0001493152-24-044766-index.html	Edgar Link	pending
0001493152-24-044766.txt	Edgar Link	pending
0001493152-24-044766-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
surg-20240930.xsd	Edgar Link	pending
surg-20240930_lab.xml	Edgar Link	unprocessable
surg-20240930_pre.xml	Edgar Link	unprocessable
surg-20240930_def.xml	Edgar Link	unprocessable
surg-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SURG
SurgePays, Inc. Stock $surg

2024 Q4 Form 10-Q Financial Statement

#000149315224044766 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG SurgePays, Inc. Stock $surg

2024 Q4 Form 10-Q Financial Statement

#000149315224044766 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG
SurgePays, Inc. Stock $surg